Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK

Imène Gouia,1 Florence Joulain,1 Yi Zhang,2 Christopher Ll Morgan,3 Asif H Khan4 1HEVA (Health Economics and Value Assessment), Sanofi, Gentilly, France; 2Medical Affairs, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA; 3Epidemiology, Pharmatelligence Ltd, Cardiff, UK; 4Global Medical, Sanofi, Br...

Full description

Saved in:
Bibliographic Details
Main Authors: Gouia I, Joulain F, Zhang Y, Morgan CL, Khan AH
Format: Article
Language:English
Published: Dove Medical Press 2025-02-01
Series:Journal of Asthma and Allergy
Subjects:
Online Access:https://www.dovepress.com/clinical-burden-and-healthcare-resource-use-of-asthma-in-children-in-t-peer-reviewed-fulltext-article-JAA
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825208879493939200
author Gouia I
Joulain F
Zhang Y
Morgan CL
Khan AH
author_facet Gouia I
Joulain F
Zhang Y
Morgan CL
Khan AH
author_sort Gouia I
collection DOAJ
description Imène Gouia,1 Florence Joulain,1 Yi Zhang,2 Christopher Ll Morgan,3 Asif H Khan4 1HEVA (Health Economics and Value Assessment), Sanofi, Gentilly, France; 2Medical Affairs, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA; 3Epidemiology, Pharmatelligence Ltd, Cardiff, UK; 4Global Medical, Sanofi, Bridgewater, NJ, USACorrespondence: Imène Gouia, Sanofi, 82 Avenue Raspail, Gentilly Cedex, 94255, France, Tel +33786980603, Email [email protected]: UK pediatric asthma prevalence is among the highest in Europe, and although the clinical and economic burden of asthma in UK adults is well described, childhood asthma data is lacking. We assessed the clinical and economic burden of asthma in children in the UK to better understand the impact of pediatric asthma.Methods: This was a retrospective, case-matched, longitudinal analysis using the Clinical Practice Research Datalink GOLD database and linked patient-level data (Hospital Episode Statistics and Office for National Statistics datasets) of selected patient (aged 6– 11 years) records in 2017. Severe exacerbation and re-exacerbation rates per patient-year (PPY), all-cause healthcare resource utilization (HCRU), and HCRU-related costs were assessed in asthma patients versus matched non-asthma controls, stratified by severity.Results: Among 5950 patients, severe exacerbation rate was 0.06, 0.17 and 0.31 PPY for mild, moderate, and severe asthma, respectively. Incident rate of severe exacerbations were higher for moderate asthma (incident rate ratios [IRR; 95% CI] 2.87 [2.30– 3.56], P< 0.0001) and severe asthma (5.19 [4.20– 6.41], P< 0.0001) versus mild asthma. Risk of re-exacerbation was significantly increased for severe versus mild asthma (hazard ratio [95% CI]: 2.98 [1.90– 4.65], P< 0.001). All-cause HCRU (IRR [95% CI]) was higher in severe asthma patients versus controls (primary care: 3.81 [3.54– 4.09], P< 0.0001; inpatient admissions: 3.23 [2.31– 4.62], P< 0.0001]); total-cost ratios relative to controls for mild, moderate, and severe asthma were 1.58 (1.39– 1.78, P< 0.0001), 2.56 (1.97– 3.33, P< 0.0001), and 3.42 (2.54– 4.61, P< 0.0001), respectively. Asthma-related costs increased with severity (total-cost ratios: moderate versus mild, 1.68 [1.45– 1.97], P< 0.0001; severe versus mild, 2.67 [2.21– 3.25], P< 0.0001).Conclusion: In children with asthma in the UK, increasing disease severity was associated with increased risk of severe exacerbations, re-exacerbations, and increased HCRU and costs.Keywords: asthma, paediatric, United Kingdom, CPRD
format Article
id doaj-art-a7c51d6d5419495e9447acfb339267b3
institution Kabale University
issn 1178-6965
language English
publishDate 2025-02-01
publisher Dove Medical Press
record_format Article
series Journal of Asthma and Allergy
spelling doaj-art-a7c51d6d5419495e9447acfb339267b32025-02-06T16:40:25ZengDove Medical PressJournal of Asthma and Allergy1178-69652025-02-01Volume 1816117199936Clinical Burden and Healthcare Resource Use of Asthma in Children in the UKGouia IJoulain FZhang YMorgan CLKhan AHImène Gouia,1 Florence Joulain,1 Yi Zhang,2 Christopher Ll Morgan,3 Asif H Khan4 1HEVA (Health Economics and Value Assessment), Sanofi, Gentilly, France; 2Medical Affairs, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA; 3Epidemiology, Pharmatelligence Ltd, Cardiff, UK; 4Global Medical, Sanofi, Bridgewater, NJ, USACorrespondence: Imène Gouia, Sanofi, 82 Avenue Raspail, Gentilly Cedex, 94255, France, Tel +33786980603, Email [email protected]: UK pediatric asthma prevalence is among the highest in Europe, and although the clinical and economic burden of asthma in UK adults is well described, childhood asthma data is lacking. We assessed the clinical and economic burden of asthma in children in the UK to better understand the impact of pediatric asthma.Methods: This was a retrospective, case-matched, longitudinal analysis using the Clinical Practice Research Datalink GOLD database and linked patient-level data (Hospital Episode Statistics and Office for National Statistics datasets) of selected patient (aged 6– 11 years) records in 2017. Severe exacerbation and re-exacerbation rates per patient-year (PPY), all-cause healthcare resource utilization (HCRU), and HCRU-related costs were assessed in asthma patients versus matched non-asthma controls, stratified by severity.Results: Among 5950 patients, severe exacerbation rate was 0.06, 0.17 and 0.31 PPY for mild, moderate, and severe asthma, respectively. Incident rate of severe exacerbations were higher for moderate asthma (incident rate ratios [IRR; 95% CI] 2.87 [2.30– 3.56], P< 0.0001) and severe asthma (5.19 [4.20– 6.41], P< 0.0001) versus mild asthma. Risk of re-exacerbation was significantly increased for severe versus mild asthma (hazard ratio [95% CI]: 2.98 [1.90– 4.65], P< 0.001). All-cause HCRU (IRR [95% CI]) was higher in severe asthma patients versus controls (primary care: 3.81 [3.54– 4.09], P< 0.0001; inpatient admissions: 3.23 [2.31– 4.62], P< 0.0001]); total-cost ratios relative to controls for mild, moderate, and severe asthma were 1.58 (1.39– 1.78, P< 0.0001), 2.56 (1.97– 3.33, P< 0.0001), and 3.42 (2.54– 4.61, P< 0.0001), respectively. Asthma-related costs increased with severity (total-cost ratios: moderate versus mild, 1.68 [1.45– 1.97], P< 0.0001; severe versus mild, 2.67 [2.21– 3.25], P< 0.0001).Conclusion: In children with asthma in the UK, increasing disease severity was associated with increased risk of severe exacerbations, re-exacerbations, and increased HCRU and costs.Keywords: asthma, paediatric, United Kingdom, CPRDhttps://www.dovepress.com/clinical-burden-and-healthcare-resource-use-of-asthma-in-children-in-t-peer-reviewed-fulltext-article-JAAasthmapaediatricunited kingdomcprd
spellingShingle Gouia I
Joulain F
Zhang Y
Morgan CL
Khan AH
Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
Journal of Asthma and Allergy
asthma
paediatric
united kingdom
cprd
title Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
title_full Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
title_fullStr Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
title_full_unstemmed Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
title_short Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
title_sort clinical burden and healthcare resource use of asthma in children in the uk
topic asthma
paediatric
united kingdom
cprd
url https://www.dovepress.com/clinical-burden-and-healthcare-resource-use-of-asthma-in-children-in-t-peer-reviewed-fulltext-article-JAA
work_keys_str_mv AT gouiai clinicalburdenandhealthcareresourceuseofasthmainchildrenintheuk
AT joulainf clinicalburdenandhealthcareresourceuseofasthmainchildrenintheuk
AT zhangy clinicalburdenandhealthcareresourceuseofasthmainchildrenintheuk
AT morgancl clinicalburdenandhealthcareresourceuseofasthmainchildrenintheuk
AT khanah clinicalburdenandhealthcareresourceuseofasthmainchildrenintheuk